of a biological differentiation in the white blood cells with a specific reference to blood transfusion. JAMA 1926; 86:1593–1597.42 42. van Rood JJ, van Leeuwen A. Leukocyte grouping: a method and its application. J Clin Invest 1963; 42:1382–1390.
43 43. Lalezari P, Radel E. Neutrophil‐specific antigens: immunology and clinical significance. Sem Hematol 1974; 11:281–290.
44 44. Perkins HA, Payne R, Ferguson J, et al. Nonhemolytic febrile transfusion reactions: quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang 1966; 11:578.
45 45. Greenwalt TJ, Gajewski M, McKenna JL. A new method for preparing buffy coat‐poor blood. Transfusion 1962; 2:221–229.
46 46. Fleming A. A simple method of removing leukocytes from blood. Br J Exp Pathol 1926; 7:282–286.
47 47. Freireich EJ, Kliman A, Gaydos LA, et al. Response to repeated platelet transfusion from the same donor. Ann Intern Med 1963; 50:277.
48 48. Murphy S, Gardner FH. Platelet preservation—effect of storage temperature on maintenance of platelet viability—deleterious effect of refrigerated storage. N Engl J Med 1969; 380:1094–1098.
49 49. Abel JJ, Rowntree LC, Turner BB. Plasma removal with return of corpuscles. J Pharmacol Exp Ther 1914; 5:625–641.
50 50. McCullough J. Introduction to apheresis donations including history and general principles. In: McLeod B, ed. Apheresis: Principles and Practice. Bethesda, MD: AABB Press, 2003, pp. 29–47.
51 51. Tullis JL, Eberle WG, Baudanza P. Platelet‐pheresis: description of a new technique. Transfusion 1968; 8:154–164.
52 52. Tullis JL, Tinch RJ, Baudanza P, et al. Plateletpheresis in a disposable system. Transfusion 1971; 11:368–377.
53 53. Freireich EJ, Judson G, Levin RH. Separation and collection of leukocytes. Cancer Res 1965; 25:1517–1520.
54 54. Buckner D, Eisel R, Perry S. Blood cell separation in the dog by continuous flow centrifugation. Blood 1968; 31:653–672.
55 55. Morse EE, Carbone PP, Freireich EJ, et al. Repeated leukapheresis of patients with chronic myelocytic leukemia. Transfusion 1996; 6:175–192.
56 56. Morse EE, Freireich EJ, Carbone PP, et al. The transfusion of leukocytes from donors with chronic myelocytic leukemia to patients with leukopenia. Transfusion 1966; 6:183–192.
57 57. Freireich EJ, Levin RH, Wang J. The function and gate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann NY Acad Sci 1965; 113:1081.
58 58. McCullough J. Leukapheresis and granulocyte transfusion. CRC Crit Rev Clin Lab Sci 1979; 10:275.
2 The Blood Supply
Jeffrey McCullough MD
2.1 Worldwide blood supply
Blood transfusion occurs in all parts of the world, but the availability, quality, and safety of the blood depends on the general status of medical care in that area. Approximately 1,215,000 units of blood are collected annually worldwide [1]. The amount of blood collected in relation to the population ranges from 50 donations per 1,000 population in industrialized countries to 0.3 donation per 1,000 in the least developed countries [1]. Thus, there is a concentration of blood transfusions in industrialized countries, with 15% of the world’s population receiving approximately 48% of the world blood supply [1]. Lack of blood is a major problem in many parts of the world.
Blood services are best provided if there is a national, or at least regional, organization [2]. It is important that the government makes a commitment to the nation’s blood supply (Table 2.1). Blood may be collected by individual hospitals, private blood banks, the Red Cross, Ministries of Health, or some other part of the national government. The number of units of blood collected at individual centers can range from a few hundred to thousands per year, and there may be extensive or little coordination and standardization. The adoption of a national blood policy is recommended, along with establishing a national organization [2]. This has been achieved in the developed world, where virtually all countries operate a national blood supply system as part of their public health structure as recommended by the World Health Organization (WHO) [2–5], and is beginning in other parts of the world [6–13]. The United States is essentially the only developed country without a single unified national blood supply organization.
Table 2.1 Key elements of a nationally coordinated blood transfusion service.
| Government commitment |
| A national blood policy |
| Formation or designation with responsibility to operate the program |
| Appointment of a suitable director |
| Appointment of qualified staff |
| Development of partnerships with appropriate nongovernment organizations |
| National guidelines for the clinical use of blood |
| Identification of low‐risk donor populations and development of strategies to promote blood donation |
| Education programs for physicians, nurses, and other appropriate staff regarding transfusion therapy |
| Systems for donor notification and counseling |
Blood transfusion safety: voluntary blood donation, national blood transfusion services, and safe and appropriate use; World Health Organization website programs and projects.
Although great progress has been made in establishing national or centralized blood transfusion services, some blood is still collected without national control or organization. In many parts of the world, there is little or no organized donor recruitment system and so the blood supply fluctuates. Donors may be friends or relatives of patients, voluntary nonremunerated volunteers (VNRDs), or paid donors. Although the WHO urges the use of VNRD, this source is inadequate in many countries, and VNRD rates range from 0% to 100%, with a median of 45% [1]. In low‐resource countries, more than almost half of blood is donated by friends or relatives of patients who are transfusion recipients (Table 2.2) [13–16]. Although these donors are considered to be volunteers, they may be donating under family pressure or they may be individuals unknown to the family who have been paid to donate blood. This is unfortunate because the risk for transfusion‐transmitted infection from first‐time [2, 15, 17] and paid donors is much higher than from volunteers [18] (see Chapter 3). These risks are further accentuated by the lack of comprehensive testing of donor blood for transfusion‐transmissible diseases that sometimes occurs in developing and least developed countries (Table 2.2). In many countries, blood donations are not tested routinely for the combination of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus, and syphilis [1]. This is because of a shortage of trained staff, unavailability of or poor quality of test kits, or infrastructure breakdowns. Sometimes transmissible disease testing is not done because the need is so urgent
